This week on Contemporary OB/GYN: July 4 to July 8
A look at what's coming to Contemporary OB/GYN® this week.
Demystifying AVMs
A peer-reviewed article on risk assessment and management of brain arteriovenous malformations in pregnancy.
Beware of “forever chemicals”
A peer-reviewed article about why and how to counsel pregnant and breastfeeding patients about the dangers of exposure to PFAS.
Prenatal exposure to antiseizure medication and autism
Prenatal exposure to the antiseizure medications topiramate and valproate may cause a significantly increased risk of neurodevelopmental disorders in offspring, according to a cohort study in JAMA Neurology.
Contemporary OB/GYN® Volume 67, No 7
Stay tuned this week for the latest issue of Contemporary OB/GYN®.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
